TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05650983

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise; Resistance exercise
Description: To investigate affect/effect of dissimilar modes of exercise, Aerobic exercise versus Resistance exercise, on execution function and psychological symptoms in heroin addicts, 1 hour of characteristic exercise protocols aiming to (a) maximize the strain on the cardiovascular system with Aerobic exercise(60-70% of heart rate recovery) and (b) promote the greatest hypertrophy response with Resistance exercise(65% of 1 repetition maximum \& repeated up to 15 time) were used. Both exercise programs were designed to match the male heroin addicts, with medium-intensity Strength-Trained for Resistance exercise and playing balloon volleyball for Aerobic exercise. Two exercise groups performed at 65% of their pre-determine peak oxygen uptake.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise; Resistance exercise
Description: To investigate affect/effect of dissimilar modes of exercise, Aerobic exercise versus Resistance exercise, on execution function and psychological symptoms in heroin addicts, 1 hour of characteristic exercise protocols aiming to (a) maximize the strain on the cardiovascular system with Aerobic exercise(60-70% of heart rate recovery) and (b) promote the greatest hypertrophy response with Resistance exercise(65% of 1 repetition maximum \& repeated up to 15 time) were used. Both exercise programs were designed to match the male heroin addicts, with medium-intensity Strength-Trained for Resistance exercise and playing balloon volleyball for Aerobic exercise. Two exercise groups performed at 65% of their pre-determine peak oxygen uptake.
Study: NCT04706039

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Performance evaluation (sensitivity and specificity) for COVID-19 diagnosis of the Vocus PTR-TOF process
Description: Each patient will be sampled to do a systematic respiratory virus infection screening (SARS-CoV-2 and Flu and RSV). Then each patient will be tested using the Vocus PTR-TOF process.~A self-answering questionnaire will be used to collect symptomatology information and date of onset of symptoms.
Study: NCT05328037

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sample collection
Description: Blood sample collection for dosage of vitamin C

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sample collection
Description: Blood sample collection for dosage of vitamin C

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sample collection
Description: Blood sample collection for dosage of vitamin C
Study: NCT05069987

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality Immersion
Description: An immersive virtual reality experience will be generated by a head mounted device which shows the user pre-recorded videos (SynVR Relax \& Distract, SyncVR Medical BV, Utrecht, The Netherlands). These videos are recorded in 360 degree views and matched with the users' viewing direction by the head mounted device matches. The user will not be able to see its in vivo surroundings (i.e. the Cathlab) and will be focused on the digital content. The VR immersion will be put into place throughout the entire TAVR procedure starting before femoral access obtainment and ending after access closure.
Study: NCT05689411

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Musical Toy
Description: The child and his parents in the experimental group were distracted by playing with the xylophone, a musical toy, 5 minutes before the peripheral vascular access procedure. The xylophone is a percussion wooden toy. There are two wooden bars on the xylophone that make melodious sounds when the metal plates are struck. The xylophone toy was introduced to the child and the parent, and they were given the opportunity to examine it. Before the procedure, one of the wooden sticks of the toy was given to the child and the other to the parent. Before, during and after the procedure, the child and his parents played together by making a melodic sound from the musical toy xylophone. While the child and his parents were playing with the toy, the researcher attached a tourniquet to the appropriate extremity of the child and determined the vein to which the vascular access would be performed.
Study: NCT04513002

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Triheptanoin
Description: Triheptanoin is a highly purified, synthetic medium odd-chain triglyceride that is catabolized to heptanoate.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Triheptanoin
Description: Triheptanoin is a highly purified, synthetic medium odd-chain triglyceride that is catabolized to heptanoate.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Triheptanoin
Description: Triheptanoin is a highly purified, synthetic medium odd-chain triglyceride that is catabolized to heptanoate.
Study: NCT04569721

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CT Guided Splanchnic Cryoablation
Description: The patient will be sedated and continuously monitored by the anesthesia team, who will be present for the entire procedure. The puncture site will be anesthetized with 1% Lidocaine infiltration. Following tract anesthesia, and utilizing fluoroscopic CT guidance, four cryoablation probes (Ice Rods®) will be advanced, 2 on each side. In addition, a temperature monitoring probe (Boston Scientific, Multipoint 1.5 Thermal Sensor®) will be advanced on each side. The cryoablation process will include a 10-minute freeze, followed by a 3-minute passive thaw, and a brief active thaw to facilitate probe removal. A final scan will be obtained following removal of the probes. After the procedure, a sterile dressing will be applied, and subjects will be monitored for at least 12 hours in an observation bed in the hospital post-procedure.
Study: NCT06457581

Intervention type: OTHER
Group type: OTHER
Intervention: Dry Needling
Description: Group A will undergo dry needling sessions twice a week over eight weeks, specifically targeting trigger points and tender points. Simultaneously, a consistent dosage of selective serotonin reuptake inhibitor (SSRI) will be administered and maintained throughout the entire duration of the study.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Trigger points injections
Description: Group B will undergo a comprehensive intervention involving trigger point injections administered biweekly over eight weeks. These injections will specifically target trigger points. Additionally, a control measure will be implemented through simulated needling at non-specific points.

Intervention type: DRUG
Group type: OTHER
Intervention: serotonin reuptake inhibitor (SSRI)
Description: serotonin reuptake inhibitor (SSRI)
Study: NCT05792735

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadonilimab Injection
Description: Cadonilimab, an anti-CTLA-4/PD-1 bispecific antibody, at a dose of 6mg/kg is given in combination with chemotherapy every 2 weeks preoperatively and postoperatively.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Short-course radiotherapy
Description: Preoperative short-course radiotherapy (5x5 Gy)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Consolidation chemotherapy
Description: Oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, 5-fluorouracil bolus 400 mg/m2 on day 1, and 5-fluorouracil infusion 2400 mg/m2 for 48 h) every 2 weeks for total 6 cycles preoperatively and postoperatively.
Study: NCT04864444

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine
Description: DHA-PPQ will be given over the course of three consecutive days using 160mg/20mg or 320mg/40mg of dihydroartemisinin/piperaquine tablets. DHA-PPQ will be administered via age-based dosing. All three doses will be directly observed and given orally with water and without food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Primaquine
Description: Primaquine will be given once with the first dose of DHA-PPQ. Primaquine will be administered in an aqueous solution according to age-based dosing guidelines.
Study: NCT05552911

Intervention type: PROCEDURE
Intervention: Pretreatment strategies before drug balloon therapy
Description: Preconditioning strategies for the treatment of in de novo coronary lesions using drug-coated balloons.

Intervention type: PROCEDURE
Intervention: Pretreatment strategies before drug balloon therapy
Description: Preconditioning strategies for the treatment of in de novo coronary lesions using drug-coated balloons.

Intervention type: PROCEDURE
Intervention: Different types of in-stent restenosis were treated with drug-coated balloons
Description: A new classification method of ISR lesions was proposed to observe the clinical prognosis of different ISR lesions treated with drug-coated balloon.

Intervention type: PROCEDURE
Intervention: Different types of in-stent restenosis were treated with drug-coated balloons
Description: A new classification method of ISR lesions was proposed to observe the clinical prognosis of different ISR lesions treated with drug-coated balloon.

Intervention type: PROCEDURE
Intervention: Different types of in-stent restenosis were treated with drug-coated balloons
Description: A new classification method of ISR lesions was proposed to observe the clinical prognosis of different ISR lesions treated with drug-coated balloon.

Intervention type: PROCEDURE
Intervention: Different types of in-stent restenosis were treated with drug-coated balloons
Description: A new classification method of ISR lesions was proposed to observe the clinical prognosis of different ISR lesions treated with drug-coated balloon.
Study: NCT06537843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax, PO (tablet), 200 - 400mg, once-daily, 10 days per cycle (cycle 1), 5 days per cycle (cycle 2 and subsequent cycles).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine Injection
Description: Cytarabine, Subcutaneous injection, 10 - 100mg per square meter, once-daily, 10 days per cycle (cycle 1), 5 days per cycle (cycle 2 and subsequent cycles).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin, PO (tablet), 850mg, three times a day, 10 days per cycle (cycle 1), 5 days per cycle (cycle 2 and subsequent cycles).
Study: NCT04902846

Intervention type: DIAGNOSTIC_TEST
Intervention: Early kidney damage biomarkers
Description: In the urine samples of these patients, a series of biomarkers of early kidney damage and / or predisposition to kidney damage will be measured.

Intervention type: DIAGNOSTIC_TEST
Intervention: Early kidney damage biomarkers
Description: In the urine samples of these patients, a series of biomarkers of early kidney damage and / or predisposition to kidney damage will be measured.

Intervention type: DIAGNOSTIC_TEST
Intervention: Predisposition to kidney injury biomarkers
Description: In the urine samples of these patients, a series of biomarkers of predisposition to kidney damage will be measured.

Intervention type: DIAGNOSTIC_TEST
Intervention: Predisposition to kidney injury biomarkers
Description: In the urine samples of these patients, a series of biomarkers of predisposition to kidney damage will be measured.
Study: NCT05618743

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non Surgical Periodontal Therapy
Description: Scaling and root planing using scalers and periodontal curettes will be done

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non Surgical Periodontal Therapy
Description: Scaling and root planing using scalers and periodontal curettes will be done
Study: NCT06322771

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Questionnaire about acceptance

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Questionnaire about refusal
Study: NCT06076577

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prehabilitation Exercise Group
Description: A set of core stabilization exercises and scoliosis specific exercises will be given to patients.
Study: NCT05456477

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Beef
Description: Beef entrees

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Poultry
Description: Poultry entrees
Study: NCT04677348

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pericapsular nerve group (PENG) block
Description: ultrasound-guided PENG block with 0.3% ropivacaine 20cc

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fascia iliaca compartment block (FICB)
Description: ultrasound-guided suprainguinal FICB with 0.3% ropivacaine 30cc
Study: NCT06208020

Intervention type: OTHER
Intervention: Functional near-infrared spectroscopy (fNIRS) detection
Description: fNIRS( NirScan Danyang Huichuang Medical Equipment Co. Ltd., China) will be used to detect changes in HbO and HbR during rest and voluntary swallowing. The swallowing procedure will be used consisted of three phases of manipulations: 30-s resting state periods, 30-s swallowing periods and 30-s resting state periods. A pre-collection will be conducted before the formal collection so that the subjects could understand the test process. After the pre-collection, the subjects will take a rest for 5 minutes before the formal collection.

Intervention type: OTHER
Intervention: Functional near-infrared spectroscopy (fNIRS) detection
Description: fNIRS( NirScan Danyang Huichuang Medical Equipment Co. Ltd., China) will be used to detect changes in HbO and HbR during rest and voluntary swallowing. The swallowing procedure will be used consisted of three phases of manipulations: 30-s resting state periods, 30-s swallowing periods and 30-s resting state periods. A pre-collection will be conducted before the formal collection so that the subjects could understand the test process. After the pre-collection, the subjects will take a rest for 5 minutes before the formal collection.
Study: NCT04596475

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glecaprevir/pibrentasvir (GLE/PIB)
Description: The study intervention consists of a single daily dose of GLE/PIB 100/40 mg (one dose consists of 3 tablets) administered orally; or crushed and administered via a feeding tube if participant is unable to swallow by mouth, for example in the immediate post-operative period. First dose will be administered in the pre-operative period within 4 hours of surgery followed by once daily doses for 7 days total.
Study: NCT04549701

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CAVAL US-guided Therapy
Description: Patients randomly assigned to this group will receive a daily CAVAL US exam guided decongestive therapy accessible to treating medical team, in addition to the standard care.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: Standard of care will be provided.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Standard of care will be provided.
Study: NCT05698680

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone 30 mg Tablet
Description: See treatment arm Prednisolone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine 0.5 mg Oral Tablet
Description: See treatment arm Colchicine
Study: NCT04436146

Intervention type: OTHER
Group type: OTHER
Intervention: laryngeal manual therapies
Description: The laryngeal manual therapy incorporates massaging the laryngeal muscles thus reducing excessive tension in the laryngeal and perilaryngeal musculature in patients with globus .
Study: NCT05269290

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ingavirin®, syrup, 30 mg/5 ml
Description: A dose will be based on the body weight; Ingavirin® will be administered once a day on top of standard therapy.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered once a day on top of standard therapy.
Study: NCT06458933

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sage
Description: Sage is a 12-session manualized weekly intervention delivered to people with borderline personality disorder (BPD) and their intimate partners. The Sage intervention consists of three phases: Phase 1, orientation and safety which focuses on targeting destructive behaviours (e.g., suicide attempts and self harm engagement) by providing couples with safety strategies that target suicide risk/ crisis, education about BPD, the role of emotion dysregulation and intimate relationship dysfunction in maintaining it (\~three sessions). Next, Phase 2, communication and emotion skills entails couples learning communication skills and strategies for identifying, expressing, and regulating emotions (\~five sessions). Lastly, in Phase 3, cognitive skills and intervention termination, couples learn strategies to target negative cognitions that elicit emotion dysregulation and intimate relationship dysfunction (\~four sessions).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Individual Psychotherapy
Description: Supportive Individual Psychotherapy (SIP) is a comparator in our control condition reflects enhanced usual care (i.e., case management/supportive psychotherapy) for people with BPD. Both people with BPD and partners will receive SIP sessions separately over the course of 12 sessions, delivered by therapists. For both members of the couple, SIP will involve 12 sessions of a specific form of supportive psychotherapy (referred to in other trials as case management; Linehan et al., 2015) that has been successfully used as a standard care control for individual therapy contact in BPD treatment RCTs (Linehan et al., 2015). This intervention involves conducting a needs assessment, providing resources/information (e.g., referrals), offering assistance with problems in living (e.g., eviction), and providing supportive, empathic responses.
Study: NCT04894656

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Labs, urine tests, upper endoscopy with biopsy and confocal laser endomicroscopy
Description: Tests to assess intestinal permeability

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Labs, urine tests, upper endoscopy with biopsy and confocal laser endomicroscopy
Description: Tests to assess intestinal permeability
Study: NCT05172739

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Opioid-Based Anesthesia-Analgesia Strategy
Description: A perioperative Opioid-Based multimodal Anesthesia- Analgesia strategy will be implemented that incorporates the following pharmacological agents:~Premedication: Midazolam, Anaesthesia induction \& maintenance: Midazolam, Propofol, Fentanyl, Cisatracurium or alternatively Rocuronium, Desflurane, Morphine, Paracetamol, Dexketoprofen trometamol, Ondansetron or Droperidol, Ropivacaine Surgical ward: Morphine, Paracetamol, Dexketoprofen trometamol Rescue therapy only: Tramadol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Opioid-free Anesthesia-Analgesia Strategy
Description: A perioperative Opioid-Based multimodal Anesthesia- Analgesia strategy will be implemented that incorporates the following pharmacological agents:~Premedication: Pregabalin, Midazolam, Anesthesia induction \& maintenance: Midazolam, Dexmedetomidine, Lidocaine, Propofol, Ketamine, Hyoscine, Cisatracurium or alternatively Rocuronium, Magnesium sulphate, Dexamethasone, Desflurane, Paracetamol, Dexketoprofen trometamol, Ondansetron or Droperidol, Ropivacaine, Surgical ward: Ketamine, Lidocaine, Clonidine, Droperidol and Midazolam, Pregabalin, Paracetamol, Dexketoprofen trometamol Rescue therapy only: Tramadol
Study: NCT05339672

Intervention type: OTHER
Intervention: Blood sampling - Pharmacokinetic assessment
Description: Two pharmacokinetic assessements will be performed (before start of enzalutamide and 4-6 weeks after start of enzalutamide). Each pharmacokinetic assessment consists of 9 samples (3mL blood)

Intervention type: OTHER
Intervention: Blood sampling - Pharmacokinetic assessment
Description: Two pharmacokinetic assessements will be performed (before start of enzalutamide and 4-6 weeks after start of enzalutamide). Each pharmacokinetic assessment consists of 9 samples (3mL blood)
Study: NCT05984238

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ReCET
Description: Investigational product.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide, 1.0 mg/mL
Description: Already registered medicine for type 2 diabetes

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Semaglutide, 1.0 mg/mL
Description: Already registered medicine for type 2 diabetes

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham procedure
Description: The sham control for the ReCET procedure.
Study: NCT05244681

Intervention type: OTHER
Group type: OTHER
Intervention: Semi-structured interview
Description: Semi-structured interview to explore the experience of people with chronic non-specific neck pain who used an immersive virtual reality serious game at home
Study: NCT05720780

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MS group
Description: All patients will perform the usual training by listening a piece of music of the same duration as the training. The patient will be able to choose among 4 different musical proposals corresponding to 4 different styles: rock, modern, jazz and classical. The song chosen by the patient will be the musical support for all the sessions of training on the cycle ergometer. The musical pieces will be composed with a constant rhythm (bpm=60) which, from a tonal point of view, will echo the pedaling movement. The constant rhythm will be superimposed on musical patterns in the form of loops in the styles mentioned. The musical support will assume a priming (activation) and dragging (synchronization) function, facilitating movement planning/synchronization and creating a pleasant context in which to carry out training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: C group
Description: All patients will perform 12 to 14 supervised sessions depending on the center they belong to (5-6 sessions/week) each consisting of 30 minutes of exercise at the cycle ergometer plus 3 minutes of warm-up and 3 minutes of recovery. After a warm-up phase at 0 W, the initial workload will be set to 60% of the theoretical maximum. Intensity increases or decreases of 10 W will be made according to the criteria of Maltais et al (workload will be increased when patients will report dyspnea and/or leg fatigue as ≤3 on a Borg scale modified to 10 points of perceived effort. The training load will remain unchanged if the Borg score is 4 or 5 and will be reduced for scores ≥6). Patients will have to maintain a pedaling frequency between 55 and 60 rpm.
Study: NCT05458414

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intra-operative Navigation System
Description: In the experimental group，a navigation technology was used to identify tumor margins during the surgery.